An emerging biotech with transformative potentialAbout us
Anocca is a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity.
Anocca’s technologies enable the highly precise and efficient analysis of T-cell biology required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas. With a focus on delivering TCR-modified T-cell therapies (TCR-T) in oncology, Anocca is rapidly progressing a pipeline of novel T-cell therapies towards clinical trials utilizing our own manufacturing capabilities.
Anocca’s powerful technologies are also being deployed to develop a range of novel therapeutic and prophylactic products in oncology, infectious disease and autoimmunity.
Anocca’s leadership represents diverse backgrounds and experience. Together, the Management team and Board of Directors, with collective experience from the pharmaceutical, engineering and finance sectors, along with deep scientific knowledge and business acumen, are taking the company to the next stage in its development.